WEBULL
News
TVGN
0.2549
+1.80%
0.0045
Weekly Report: what happened at TVGN last week (0202-0206)?
Weekly Report · 3d ago
Weekly Report: what happened at TVGN last week (0126-0130)?
Weekly Report · 02/02 10:33
Tevogen Bio Explores Potential One-Time Special Cash Dividend
TipRanks · 01/30 20:58
Tevogen Evaluates Potential One-Time Special Cash Dividend, Subject To Future Financial Milestones
Benzinga · 01/30 20:02
*Tevogen: Board to Evaluate Potential One-Time Special Cash Dividend >TVGN
Dow Jones · 01/30 20:01
Tevogen Bio Ties Long-Term Stock Incentives to Company Milestones
Reuters · 01/29 19:45
Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue
Barchart · 01/29 13:45
Weekly Report: what happened at TVGN last week (0119-0123)?
Weekly Report · 01/26 10:33
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 01/21 12:05
Weekly Report: what happened at TVGN last week (0112-0116)?
Weekly Report · 01/19 10:40
Tevogen Bio Holdings Inc. Announces Date for Special Stockholder Meeting
Reuters · 01/16 22:30
Tevogen Reports 2025 Milestones, Expands ExacTcell Platform And Multi-Indication CTL Pipeline; Advances In-House GMP Manufacturing Capabilities
Benzinga · 01/12 14:35
Tevogen reports scientific, operational milestones achieved in 2025
TipRanks · 01/12 14:11
Tevogen Provided Updates At J.P. Morgan Healthcare Conference
Benzinga · 01/12 14:09
Tevogen Bio Expands T Cell Therapy Pipeline and Boosts Manufacturing Capacity
Reuters · 01/12 14:00
Weekly Report: what happened at TVGN last week (0105-0109)?
Weekly Report · 01/12 10:39
Weekly Report: what happened at TVGN last week (1229-0102)?
Weekly Report · 01/05 10:32
Weekly Report: what happened at TVGN last week (1222-1226)?
Weekly Report · 12/29/2025 10:31
Tevogen CEO Donates Shares to Support Education for Underprivileged Children
Barchart · 12/22/2025 11:40
Weekly Report: what happened at TVGN last week (1215-1219)?
Weekly Report · 12/22/2025 10:31
More
Webull provides a variety of real-time TVGN stock news. You can receive the latest news about Tevogen Bio through multiple platforms. This information may help you make smarter investment decisions.
About TVGN
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.